Disease Domain | Count |
---|---|
Neoplasms | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 1 |
Top 5 Target | Count |
---|---|
SRC(Tyrosine-protein kinase SRC) | 1 |
Target |
Mechanism SRC inhibitors [+1] |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism Class I PI3K inhibitors |
Active Org.- |
Originator Org. |
Active Indication- |
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism SRC inhibitors |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Jan 2008 |
Sponsor / Collaborator |
Start Date01 Jul 2007 |
Sponsor / Collaborator |
Start Date01 Nov 2006 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
TG100435 ( SRC ) | Neoplasms More | Discovery |
T-102 ( SRC ) | Stroke More | Discontinued |
TG-100801 ( SRC x VEGFR2 ) | Choroidal Neovascularization More | Discontinued |
TG-100115 ( Class I PI3K ) | Myocardial Infarction More | Discontinued |
TG-101001 ( Raf kinase ) | Neoplasms More | Pending |